Evidence map›Paper›PMID 38643145›Full record

ArticleCancer cell international2024

High LGALS3 expression induced by HCP5/hsa-miR-27b-3p correlates with poor prognosis and tumor immune infiltration in hepatocellular carcinoma.

Yinghui Ren, Yongmei Qian, Qicheng Zhang, Xiaoping Li, Mingjiang Li, Wei Li, Pan Yang, Hengchang Ren, Hongxia Li, Yiqi Weng and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. The Role of Galectin-3 in Liver Inflammation and Fibrosis.Journal of inflammation research · 2026
    Review
  6. Article
  7. Article
  8. Cancers · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Yinghui Ren *Department of Anesthesiology, Tianjin First Central Hospital, Tianjin, 300192, China.
Yongmei Qian *Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Qicheng Zhang *Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Xiaoping LiDepartment of Thoracic Surgery, Tianjin First Central Hospital, Tianjin, 300192, China.
Mingjiang LiDepartment of Thoracic Surgery, Tianjin First Central Hospital, Tianjin, 300192, China.
Wei LiDepartment of Thoracic Surgery, Tianjin First Central Hospital, Tianjin, 300192, China.
Pan YangDepartment of Thoracic Surgery, Tianjin First Central Hospital, Tianjin, 300192, China.
Hengchang RenDepartment of Anesthesiology, Tianjin First Central Hospital, Tianjin, 300192, China.
Hongxia LiDepartment of Anesthesiology, Tianjin First Central Hospital, Tianjin, 300192, China.
Yiqi WengDepartment of Anesthesiology, Tianjin First Central Hospital, Tianjin, 300192, China.
Dengwen LiCollege of Life Sciences, Nankai University, Tianjin, 300071, China.
Ke XuTianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, 300052, China. xuke@tmu.edu.cn.
Wenli YuDepartment of Anesthesiology, Tianjin First Central Hospital, Tianjin, 300192, China. yzxwenliyu@163.com.
Tianjin Medical University · CNTianjin First Center Hospital · CNTianjin Medical University General Hospital · CNNankai University · CN

Funding

Key Project of Natural Science Foundation of Tianjin 22JCZDJC00450Natural Science Foundation of Tianjin 21JCQNJC00150Project of Health Commission of Tianjin TJWJ2021MS006Science and Technology Foundation of Tianjin Health Bureau TJWJ2022QN026Tianjin Key Medical Discipline (Specialty) Construction Project TJYXZDXK-045A
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is widely recognized for its unfavorable prognosis. Increasing evidence has revealed that LGALS3 has an essential function in initiating and developing several malignancies in humans. Nevertheless, thorough analysis of the expression profile, clinical prognosis, pathway prediction, and immune infiltration of LGALS3 has not been fully explored in HCC.

methodsIn this study, an initial pan-cancer analysis was conducted to investigate the expression and prognosis of LGALS3. Following a comprehensive analysis, which included expression analysis and correlation analysis, noncoding RNAs that contribute to the overexpression of LGALS3 were subsequently identified. This identification was further validated using HCC clinical tissue samples. TIMER2 and GEPIA2 were employed to examine the correlation between LGALS3 and HCP5 with immunological checkpoints, cell chemotaxis, and immune infiltration in HCC. The R program was applied to analyze the expression distribution of immune score in in HCC patients with high and low LGALS3 expression. The expression profiles of immune checkpoints were also analyzed. Use R to perform GSVA analysis in order to explore potential signaling pathways.

resultsFirst, we conducted pan-cancer analysis for LGALS3 expression level through an in-depth analysis of public databases and found that HCC has a high LGALS3 gene and protein expression level, which were then verified in clinical HCC specimens. Meanwhile, high LGALS3 gene expression is related to malignant progression and poor prognosis of HCC. Univariate and multivariate analyses confirmed that LGALS3 could serve as an independent prognostic marker for HCC. Next, by combining comprehensive analysis and validation on HCC clinical tissue samples, we hypothesize that the HCP5/hsa-miR-27b-3p axis could serve as the most promising LGALS3 regulation mechanism in HCC. KEGG and GO analyses highlighted that the LGALS3-related genes were involved in tumor immunity. Furthermore, we detected a significant positive association between LGALS3 and HCP5 with immunological checkpoints, cell chemotaxis, and immune infiltration. In addition, high LGALS3 expression groups had significantly higher immune cell scores and immune checkpoint expression levels. Finally, GSVA analysis was performed to predict potential signaling pathways linked to LGALS3 and HCP5 in immune evasion and metabolic reprogramming of HCC.

conclusionsOur findings indicated that the upregulation of LGALS3 via the HCP5/hsa-miR-27b-3p axis is associated with unfavorable prognosis and increased tumor immune infiltration in HCC.

Indexed as

HCP5Hepatocellular carcinomaImmune cell infiltrationLGALS3PrognosisTumor microenvironment

Identifiers

PMID38643145
PMCPMC11031979
OpenAlexW4394975775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.